Cargando…

Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

AIM: (177)Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Clinical trials prior to the FDA approval of Lu-177 showed favorable ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hentzen, Stijn, Mehta, Kathan, Al-Rajabi, Raed Moh’d Taiseer, Saeed, Anwaar, Baranda, Joaquina Celebre, Williamson, Stephen K., Sun, Weijing, Kasi, Anup
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344897/ https://www.ncbi.nlm.nih.gov/pubmed/37455826 http://dx.doi.org/10.37349/etat.2023.00141

Ejemplares similares

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020)

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study
por: Saeed, Anwaar, et al.
Publicado: (2020)

Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience
por: Al-Jumayli, Mohammed, et al.
Publicado: (2019)

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
por: Saeed, Anwaar, et al.
Publicado: (2023)

Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review
por: Kasi, Anup, et al.
Publicado: (2020)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
por: Rajapaksa, Anushi E., et al.
Publicado: (2020)

Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: A systematic review and meta-analysis
por: Park, Robin, et al.
Publicado: (2020)

In vitro Sensitivity Test of Breast Cancer Cells to Hormonal Agents in a Radionucleotide‐incorporation Assay
por: Watanabe, Toru, et al.
Publicado: (1990)

Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy
por: Kasi, Anup, et al.
Publicado: (2021)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
por: Radford, Maluki, et al.
Publicado: (2023)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer
por: Atri-Schuller, Aviva, et al.
Publicado: (2022)

Immunoglobin A Deficiency and Squamous Cell Carcinoma With a Rare Presentation as Anal Cancer
por: Kasi, Anup, et al.
Publicado: (2022)

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
por: Richardson, Gary Edward, et al.
Publicado: (2023)

The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
por: Saeed, Anwaar, et al.
Publicado: (2021)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

Is obesity a risk factor in cancer patients with COVID-19?
por: Park, Robin, et al.
Publicado: (2021)

Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials
por: Park, Robin, et al.
Publicado: (2021)

Neuroendocrine Tumor Involving the Epicardium
por: Soyano, Aixa E., et al.
Publicado: (2017)

Microsatellite Instability with BRAF V600E Associated with Delayed Presentation but Poor Survival in Stage III Colorectal Cancer
por: Karki, Sophiya, et al.
Publicado: (2023)

Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
por: Johnson, Braden M., et al.
Publicado: (2022)

Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chidharla, Anusha, et al.
Publicado: (2023)

Natural Frequencies Optimization of Thin-Walled Circular Cylindrical Shells Using Axially Functionally Graded Materials
por: Alshabatat, Nabeel Taiseer
Publicado: (2022)

Immunotherapy in genitourinary malignancies
por: Mehta, Kathan, et al.
Publicado: (2017)

Important updates from the AACR virtual meeting: COVID-19 and cancer
por: Ripp, Jacob, et al.
Publicado: (2020)

Benign Oral Masses in a Northern Jordanian Population-a Retrospective Study
por: Al-Khateeb, Taiseer Hussain
Publicado: (2009)

Editorial: Hepatocellular carcinoma: from personalized medicine to practical guidelines
por: El-Nakeep, Sarah, et al.
Publicado: (2023)

Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
por: Loosen, Sven H., et al.
Publicado: (2022)

Desarrollo de aplicaciones con Access 2000 /
por: Hentzen, Whil
Publicado: (2001)

The business case for Visual FoxPro in 2013
por: Hentzen, Whil
Publicado: (2012)

So you've inherited a Visual FoxPro application: now what ?
por: Hentzen, Whil
Publicado: (2012)

Dealing with reserved words as data names in a VFP application
por: Hentzen, Whil
Publicado: (2013)

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications
por: Saeed, Anwaar, et al.
Publicado: (2020)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma
por: Mehta, Kathan, et al.
Publicado: (2015)

Adapting to the Sharing Economy
por: Kathan, Wolfgang
Publicado: (2015)

Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review
por: Huang, Chengliang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5iq46pgje7iktije726gtpv34h